About Diacylglycerol O-acyltransferase 2-like protein 6
Diacylglycerol O-acyltransferase 2-like protein 6 (DGAT2L6) is a protein
from Homo sapiens identified by UniProt accession
Q6ZPD8, 337 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Diacylglycerol O-acyltransferase 2-like protein 6 |
|---|
| UniProt accession | Q6ZPD8 |
|---|
| Gene | DGAT2L6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 337 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (10)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.18
- adolescent idiopathic scoliosis · score 0.18
- breast adenocarcinoma · score 0.18
- prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- Familial prostate cancer · score 0.11
- isolated asymptomatic elevation of creatine phosphokinase · score 0.05
- pentosuria · score 0.04
- psoriasis · score 0.02
- neoplasm · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6ZPD8-F1 | alphafold | PREDICTED | 92.14 | — |
Amino-acid sequence (337 residues)
MAFFSRLNLQ EGLQTFFVLQ WIPVYIFLGA IPILLIPYFL LFSKFWPLAV LSLAWLTYDW NTHSQGGRRS AWVRNWTLWK YFRNYFPVKL VKTHDLSPKH NYIIANHPHG ILSFGVFINF ATEATGIARI FPSITPFVGT LERIFWIPIV REYVMSMGVC PVSSSALKYL LTQKGSGNAV VIVVGGAAEA LLCRPGASTL FLKQRKGFVK MALQTGAYLV PSYSFGENEV FNQETFPEGT WLRLFQKTFQ DTFKKILGLN FCTFHGRGFT RGSWGFLPFN RPITTVVGEP LPIPRIKRPN QKTVDKYHAL YISALRKLFD QHKVEYGLPE TQELTIT
Explore Diacylglycerol O-acyltransferase 2-like protein 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets